Release
2022/07/01
OSAKA, Japan, July 1, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "SHIONOGI") announced that SHIONOGI is launching its new group brand globally, reflecting the company’s commitment to pursue innovation, shape the future of healthcare, and sustainably grow while helping to meet the healthcare needs of society. Our new brand mark has been created as a visual embodiment of this commitment.
In June 2020, SHIONOGI published its new Medium-Term Business Plan “Shionogi Transformation Strategy 2030 (STS2030)”, describing our vision for the future of healthcare in 2030 and our strategy for achieving that vision. The COVID-19 pandemic, which has spread exponentially around the world, continues to have a major impact on people’s lives and livelihood. As a leading company in the fight against infectious disease, SHIONOGI has been working intensively to provide solutions to the current crisis, as well as to address other current and future infectious disease threats, such as antimicrobial resistance (AMR). The battle to protect society against the ravages of infectious disease is a core part of SHIONOGI's mission, which we pursue while also developing and offering innovative healthcare solutions across a range of therapeutic areas and transforming our business to drive sustainable mid-to-long term growth.
The new group brand mark has been refined and modernized, with improved visibility of the “FUNDOH” (weight) motif, which is a symbol of accuracy and trust that has been a long-established avatar for SHIONOGI’s mission. The brand mark combines the FUNDOH embodiment of Reliable Weight, reflecting our unwavering commitment to earning our stakeholders’ trust and confidence, built over 144 years, with the Dynamic One Ring, representing not only the unity of the entire global SHIONOGI organization, but also our intention to continuously expand the scope of our contribution to healthcare, both in terms the range of solutions we provide, and in terms of the global scope across which we offer them, concomitantly contributing to the sustainable growth of our business.
By working to address the healthcare needs of people around the world, we will realize the SHIONOGI Group Vision expressed in STS2030, "Building Innovation Platforms to Shape the Future of Healthcare". We will continue to drive innovation and to deliver meaningful solutions that bring value to all of our stakeholders, now and into the future.
###
References
●Reliable Weight
This shape is based on weights used during the Edo period to precisely measure the quantities of medicines and is therefore a symbol of accuracy, reliability, and honesty. It expresses the trust and stakeholder confidence that SHIONOGI has cultivated so far, which is the heritage that we want to pass on to the future.
●Dynamic One Ring
The Dynamic One Ring is a ring that represents both unity (connection) and expansion. Unity means not only strong cooperation within the SHIONOGI Group, but also our connections with our wide and growing range of partners and collaborators around the world, as well as with all of our stakeholders. The ring also represents the fact that the range of healthcare products we offer will expand, along with the territorial scope across which we provide them, and our contribution to society will increase accordingly.
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html